What is a stock summary page? Click here for an overview.
Business Description
BerGenBio ASA
ISIN : NO0013251173
Description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 171.34 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -68.4 | |||||
| 3-Year EBITDA Growth Rate | 76.7 | |||||
| 3-Year EPS without NRI Growth Rate | 76.5 | |||||
| 3-Year FCF Growth Rate | 75.6 | |||||
| 3-Year Book Growth Rate | -79.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.9 | |||||
| 9-Day RSI | 37.8 | |||||
| 14-Day RSI | 35.21 | |||||
| 3-1 Month Momentum % | -82.68 | |||||
| 6-1 Month Momentum % | -83.46 | |||||
| 12-1 Month Momentum % | -89.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.79 | |||||
| Quick Ratio | 4.79 | |||||
| Cash Ratio | 4.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -236.6 | |||||
| Shareholder Yield % | -193.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -17833.73 | |||||
| Net Margin % | -16424.65 | |||||
| FCF Margin % | -18354.17 | |||||
| ROE % | -103.61 | |||||
| ROA % | -79.25 | |||||
| ROIC % | -536.66 | |||||
| 3-Year ROIIC % | -871.62 | |||||
| ROC (Joel Greenblatt) % | -28670.86 | |||||
| ROCE % | -99.99 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 80 | |||||
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | 0.52 | |||||
| EV-to-Forward-EBIT | -1.01 | |||||
| EV-to-EBITDA | 0.52 | |||||
| EV-to-Forward-EBITDA | -1.01 | |||||
| EV-to-Revenue | -83.9 | |||||
| EV-to-Forward-Revenue | 1543.51 | |||||
| EV-to-FCF | 0.44 | |||||
| Price-to-GF-Value | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.55 | |||||
| Price-to-Net-Cash | 0.62 | |||||
| Earnings Yield (Greenblatt) % | 189.53 | |||||
| FCF Yield % | -223.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
BerGenBio ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.072 | ||
| EPS (TTM) (€) | -0.324 | ||
| Beta | 51.39 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 10.75 | ||
| Volatility % | 96 | ||
| 14-Day RSI | 35.21 | ||
| 14-Day ATR (€) | 0.036833 | ||
| 20-Day SMA (€) | 0.1152 | ||
| 12-1 Month Momentum % | -89.88 | ||
| 52-Week Range (€) | 0.0819 - 1.44 | ||
| Shares Outstanding (Mil) | 39.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BerGenBio ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BerGenBio ASA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BerGenBio ASA Frequently Asked Questions
What is BerGenBio ASA(FRA:7BG0)'s stock price today?
The current price of FRA:7BG0 is €0.11. The 52 week high of FRA:7BG0 is €1.44 and 52 week low is €0.08.
When is next earnings date of BerGenBio ASA(FRA:7BG0)?
The next earnings date of BerGenBio ASA(FRA:7BG0) is 2025-05-21.
Does BerGenBio ASA(FRA:7BG0) pay dividends? If so, how much?
BerGenBio ASA(FRA:7BG0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers